Video 8
Video1Video2Video3Video4Video5Video6Video7Video8Video9Video10Video11Video12Video13 (Mexico)Video14Video15( Espanol)Video16
Disclaimer: Individual results vary. Anti-TNF treatment for the indications below is off-label. Please see the Legal Disclaimer. Maintenance dosing, usually weekly, but sometimes as little as monthly, is necessary for optimal effect. The methods of anti-TNF treatment utilized for these patients are patented inventions of the INR[1].
Sustained improvement through one year following perispinal etanercept (2009)* video length 2:39

This video was filmed in Los Angeles in February 2009 and August and September 2008, and includes an interview of the patient and her daughter. Please see Perispinal etanercept for neuroinflammatory disorders. Edward Tobinick MD. Drug Discovery Today 2009 Feb; 14(3-4):168-77.
The videos above are interviews discussing and documenting the clinical response to initiation of anti-TNF treatment (perispinal etanercept) at the INR. For the published results please see Tobinick E, Gross H, Weinberger A, Cohen H., TNF-alpha Modulation for Treatment of Alzheimer's Disease: A 6-Month Pilot Study MedGenMed 2006; 8(2) :25; Tobinick E., Perispinal etanercept for treatment of Alzheimer's disease, Current Alzheimer Research 2007 Dec; 4(5):550-2; Tobinick E, Gross H., Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease, BMC Neurology 2008; 8:27; and Tobinick E., Perispinal etanercept for neuroinflammatory disorders, Drug Discovery Today 2009 Feb; 14(3-4):168-77.
Institute for Neurological Research, a private medical group, inc.
100 UCLA Medical Plaza, Suites 205-210 Los Angeles, California 90095

Appointments and Information: (310) 824-6199
Copyright ©2009, the Institute for Neurological Research® (INR®), a private medical group, inc., all rights reserved. [1]U.S. patents 6,982,089 and 7,214,658, and additional issued and pending U.S. and foreign patents. These patents are assigned to TACT IP LLC. Please see the medical and legal disclaimer.

*Perispinal etanercept for Alzheimer's disease and other forms of dementia is a patented, off-label treatment method developed at the INR.
Return to Home Page
<Alzheimer's Treatment at the INR (pdf document)><Referrals to the INR><Map and Directions><Appointments><Terms of Use><Dementia>